2011
Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome
Lu L, Zhang C, Zhu G, Irwin M, Risch H, Menato G, Mitidieri M, Katsaros D, Yu H. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Research 2011, 13: r56. PMID: 21645396, PMCID: PMC3218945, DOI: 10.1186/bcr2893.Peer-Reviewed Original ResearchConceptsEndocrine therapyDisease outcomeAdjuvant treatmentTelomerase expressionBetter survival outcomesDisease-free survivalHormone receptor statusBreast cancer patientsRisk of deathTelomere lengthHigh telomeraseCause-specific mortalityBreast cancer prognosisBreast cancer cellsCancer cell resistanceHigh telomerase expressionOverall survivalPatient ageDisease recurrenceReceptor statusHistological typeAggressive diseaseSurvival outcomesDisease stageCancer patients
1997
Breast Cancer Risk Factors According to Combined Estrogen and Progesterone Receptor Status: A Case-Control Analysis
Yoo K, Tajima K, Miura S, Takeuchi T, Hirose K, Risch H, Dubrow R. Breast Cancer Risk Factors According to Combined Estrogen and Progesterone Receptor Status: A Case-Control Analysis. American Journal Of Epidemiology 1997, 146: 307-314. PMID: 9270409, DOI: 10.1093/oxfordjournals.aje.a009271.Peer-Reviewed Original ResearchConceptsProgesterone receptor statusHormone receptor statusReceptor statusEstrogen receptor statusRisk factorsBreast cancerAichi Cancer Center HospitalBreast cancer risk factorsDiagnosis/interviewReproductive risk factorsCancer Center HospitalCancer risk factorsGradient of riskBreast cancer casesCase-control analysisPolytomous logistic regressionCancer-free controlsCommon control groupStratification of casesJoint estrogenCenter HospitalMenstrual regularityCigarette smokingCombined EstrogenProgesterone receptor